We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VIVUS Inc | NASDAQ:VVUS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.4665 | 0.4625 | 0.4626 | 0 | 01:00:00 |
To listen via webcast, please visit http://ir.vivus.com/, or by clicking here.
To listen via phone, please use the dial in information provided below.
Dial in Details:Toll-Free: (877) 359-2916International: (224) 357-2386Passcode: 6939389
A webcast replay will be available on the VIVUS website for 30 days.
About VIVUSVIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs. For more information about VIVUS, please visit www.vivus.com.
Forward-Looking StatementsCertain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “opportunity” and “should,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS’ Form 10-K for the year ended December 31, 2019 as filed on March 3, 2020, and as amended by the Form 10-K/A filed on April 29, 2020, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.
CONTACT: | ||
VIVUS, Inc. | Investor Relations: Lazar FINN Partners | |
Mark Oki | David Carey | |
Chief Financial Officer | Senior Partner | |
oki@vivus.com | david.carey@finnpartners.com | |
650-934-5200 | 212-867-1768 |
1 Year VIVUS Chart |
1 Month VIVUS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions